Mesilato de fentolamina en la reversión de la anestesia local en odontologíarepercusión en el postoperatorio del paciente

  1. Gago García, Alejandro
Zuzendaria:
  1. Jesús Seco Calvo Zuzendaria
  2. Mariano del Canto Pingarrón Zuzendaria

Defentsa unibertsitatea: Universidad de León

Fecha de defensa: 2021(e)ko maiatza-(a)k 07

Epaimahaia:
  1. Rafael Baca Pérez Bryan Presidentea
  2. Vicente Rodríguez Pérez Idazkaria
  3. Enrique Echevarría Orella Kidea
Saila:
  1. DEP. DE ENFERMERÍA Y FISIOTERAPIA

Mota: Tesia

Teseo: 655793 DIALNET

Laburpena

Background: To evaluate changes in the effectiveness of phentolamine mesylate in combination with different local anesthetics (LAs) and vasoconstrictors. A prospective randomized double-blind study was conducted with 90 patients divided into three groups, with each group being administered one of three different LAs: lidocaine 2% 1/80,000, articaine 4% 1/200,000, and bupivacaine 0.5% 1/200,000. Methods: We compared treatments administered to the mandible involving a LA blockade of the inferior alveolar nerve. Results were assessed by evaluating reduction in total duration of anesthesia, self-reported patient comfort using the visual analog pain scale, incidence rates of the most common adverse effects, overall patient satisfaction, and patient feedback. Results: The differences among the three groups were highly significant (P < 0.001); time under anesthesia was especially reduced for both the lip and tongue with bupivacaine. The following adverse effects were reported: pain at the site of the anesthetic injection (11.1%), headaches (6.7%), tachycardia (1.1%), and heavy bleeding after treatment (3.3%). The patients’ feedback and satisfaction ratings were 100% and 98.9%, respectively. Conclusions: Efficient reversal of LAs is useful in dentistry as it allows patients to return to normal life more readily and avoid common self-injuries sometimes caused by anesthesia. Phentolamine mesylate reduced the duration of anesthesia in the three studied groups, with the highest reduction reported in the bupivacaine group (from 460 min to 230 min for the lip and 270 min for the tongue [P < 0.001]).